DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations

DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations

Background: Breast cancers can be divided into HER2-negative and HER2-positive subtypes according to different status of HER2 gene. Despite extensive studies connecting germline mutations with possible risk of HER2-negative breast cancer, the main category of breast cancer, it remains challenging to...

Full description

Bibliographic Details
Main Authors: Mei Yang, Yanhui Fan, Zhi-Yong Wu, Jin Gu, Zhendong Feng, Qiangzu Zhang, Shunhua Han, Zhonghai Zhang, Xu Li, Yi-Ching Hsueh, Yanxiang Ni, Xiaoling Li, Jieqing Li, Meixia Hu, Weiping Li, Hongfei Gao, Ciqiu Yang, Chunming Zhang, Liulu Zhang, Teng Zhu, Minyi Cheng, Fei Ji, Juntao Xu, Hening Cui, Guangming Tan, Michael Q. Zhang, Changhong Liang, Zaiyi Liu, You-Qiang Song, Gang Niu, Kun Wang
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:EBioMedicine
Subjects:
HER2-negative breast cancer
Germline rare coding mutations
Damage assessment of genomic mutations (DAGM)
Risk assessment
Activity profiles of signalling pathways (APSP)
HER2 signalling pathway
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421002395

Internet

http://www.sciencedirect.com/science/article/pii/S2352396421002395

Similar Items